Es gibt 1 Publikation für dieses Produkt. Der Kaninchen Polyklonal anti-IL-33 Antikörper wird verwendet zum Nachweis von IL-33 in Proben von Human. Er wurde validiert für WB, ELISA und IHC.
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
Lot specific
Buffer
0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Konservierungsmittel
Without preservative
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Short Term Storage: +4°C Long Term Storage: -20°C Stable for at least 6 months after receipt when stored at -20°C.
Haltbarkeit
6 months
Carriere, Roussel, Ortega, Lacorre, Americh, Aguilar, Bouche, Girard: "IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 1, pp. 282-7, (2007) (PubMed).
Target
IL-33 (IL33)
(Interleukin 33 (IL33))
Andere Bezeichnung
IL-33
Hintergrund
Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30 kDa human IL33 is converted by CASP1 to a 18 kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.